DPP-4 inhibition improves early mortality, β cell function, and adipose tissue inflammation in db/db mice fed a diet containing sucrose and linoleic acid

Diabetology and Metabolic Syndrome

Volumn 8, Issue 1, 2016, Pages

  Shirakawa, Jun ^a   Okuyama, Tomoko ^a   Kyohara, Mayu ^a   Yoshida, Eiko ^a   Togashi, Yu ^a   Tajima, Kazuki ^a   Yamazaki, Shunsuke ^a   Kaji, Mitsuyo ^a   Koganei, Megumi ^b   Sasaki, Hajime ^b,c   Terauchi, Yasuo ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b MEIJI DAIRIES CORPORATION   (Japan)

^c KANAGAWA INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Adipose tissue; DPP 4 inhibitor; Insulin resistance; Life span; Pancreatic cell; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; LINOLEIC ACID; MK 0626; OLEIC ACID; SITAGLIPTIN; SUCROSE; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL LOSS; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME INHIBITION; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; MALE; MORTALITY; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

EID: 84978760214     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/s13098-016-0138-4     Document Type: Article

References (51)

1. Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med. 2007;167(11):1145-51. doi: 10.1001/archinte.167.11.1145.
2. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet. 2006;368(9529):29-36. doi: 10.1016/S0140-6736(06)68967-8.
3. Clancy DJ, Gems D, Harshman LG, Oldham S, Stocker H, Hafen E, et al. Extension of life-span by loss of CHICO, a Drosophila insulin receptor substrate protein. Science. 2001;292(5514):104-6. doi: 10.1126/science.1057991.
4. Bartke A. Impact of reduced insulin-like growth factor-1/insulin signaling on aging in mammals: novel findings. Aging Cell. 2008;7(3):285-90. doi: 10.1111/j.1474-9726.2008.00387.x.
5. Valencak TG, Ruf T. Feeding into old age: long-term effects of dietary fatty acid supplementation on tissue composition and life span in mice. J Comp Physiol B. 2011;181(2):289-98. doi: 10.1007/s00360-010-0520-8.
6. Hodson L, Skeaff CM, Fielding BA. Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. Prog Lipid Res. 2008;47(5):348-80. doi: 10.1016/j.plipres.2008.03.003.
7. Shirakawa J, Amo K, Ohminami H, Orime K, Togashi Y, Ito Y, et al. Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased beta cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes. J Biol Chem. 2011;286(29):25467-76. doi: 10.1074/jbc.M110.217216.
8. Shirakawa J, Fujii H, Ohnuma K, Sato K, Ito Y, Kaji M, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes. 2011;60(4):1246-57. doi: 10.2337/db10-1338.
9. Sato K, Arai H, Mizuno A, Fukaya M, Sato T, Koganei M, et al. Dietary palatinose and oleic acid ameliorate disorders of glucose and lipid metabolism in Zucker fatty rats. J Nutr. 2007;137(8):1908-15.
10. Chattipakorn N, Apaijai N, Chattipakorn SC. Dipeptidyl peptidase-4 inhibitors and the ischemic heart: additional benefits beyond glycemic control. Int J Cardiol. 2016;202:415-6. doi: 10.1016/j.ijcard.2015.09.044.
11. Angeli FS, Shannon RP. Incretin-based therapies: can we achieve glycemic control and cardioprotection? J Endocrinol. 2014;221(1):T17-30. doi: 10.1530/JOE-13-0195.
12. Monami M, Ahren B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-Analysis of randomized clinical trials. Diab Obes Metab. 2013;15(2):112-20. doi: 10.1111/dom.12000.
13. Omar BA, Vikman J, Winzell MS, Voss U, Ekblad E, Foley JE, et al. Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-Aged diet-induced obesity mouse model. Diabetologia. 2013;56(8):1752-60. doi: 10.1007/s00125-013-2927-8.
14. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. New England J Med. 2013;369(14):1317-26. doi: 10.1056/NEJMoa1307684.
15. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. New England J Med. 2013;369(14):1327-35. doi: 10.1056/NEJMoa1305889.
16. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell. 1996;84(3):491-5.
17. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 1995;269(5223):543-6.
18. Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature. 2013;503(7477):493-9. doi: 10.1038/nature12656.
19. Tamemoto H, Kadowaki T, Tobe K, Yagi T, Sakura H, Hayakawa T, et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature. 1994;372(6502):182-6. doi: 10.1038/372182a0.
20. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-A]pyrazin-7(8H)- yl]-1-(2,4,5-trifluorophenyl)butan-2-Amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005;48(1):141-51. doi: 10.1021/jm0493156.
21. Edmondson SD, Mastracchio A, Mathvink RJ, He J, Harper B, Park YJ, et al. (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N, N-dimethyl-4-oxo-2-(4-[1,2,4]tr iazolo[1,5-A]-pyridin-6-ylphenyl)butanamide: a selective alpha-Amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2006;49(12):3614-27. doi: 10.1021/jm060015t.
22. Shirakawa J, Okuyama T, Yoshida E, Shimizu M, Horigome Y, Tuno T, et al. Effects of the antitumor drug OSI-906, a dual inhibitor of IGF-1 receptor and insulin receptor, on the glycemic control, beta-cell functions, and beta-cell proliferation in male mice. Endocrinology. 2014;155(6):2102-11. doi: 10.1210/en.2013-2032.
23. Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011;60(7):1917-25. doi: 10.2337/db10-1707.
24. Dalboge LS, Almholt DL, Neerup TS, Vassiliadis E, Vrang N, Pedersen L, et al. Characterisation of age-dependent beta cell dynamics in the male db/db mice. PLoS One. 2013;8(12):e82813. doi: 10.1371/journal.pone.0082813.
25. Shirakawa J, Tanami R, Togashi Y, Tajima K, Orime K, Kubota N, et al. Effects of liraglutide on beta-cell-specific glucokinase-deficient neonatal mice. Endocrinology. 2012;153(7):3066-75. doi: 10.1210/en.2012-1165.
26. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821-30. doi: 10.1172/JCI19451.
27. Terauchi Y, Sakura H, Yasuda K, Iwamoto K, Takahashi N, Ito K, et al. Pancreatic beta-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose. J Biol Chem. 1995;270(51):30253-6.
28. Terauchi Y, Takamoto I, Kubota N, Matsui J, Suzuki R, Komeda K, et al. Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest. 2007;117(1):246-57. doi: 10.1172/JCI17645.
29. Shirakawa J, Togashi Y, Sakamoto E, Kaji M, Tajima K, Orime K, et al. Glucokinase activation ameliorates ER stress-induced apoptosis in pancreatic beta-cells. Diabetes. 2013;62(10):3448-58. doi: 10.2337/db13-0052.
30. Fyfe MC, White JR, Taylor A, Chatfield R, Wargent E, Printz RL, et al. Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions. Diabetologia. 2007;50(6):1277-87. doi: 10.1007/s00125-007-0646-8.
31. Kulkarni RN, Winnay JN, Daniels M, Bruning JC, Flier SN, Hanahan D, et al. Altered function of insulin receptor substrate-1-deficient mouse islets and cultured beta-cell lines. J Clin Invest. 1999;104(12):R69-75. doi: 10.1172/JCI8339.
32. Greer JJ, Ware DP, Lefer DJ. Myocardial infarction and heart failure in the db/db diabetic mouse. Am J Physiol Heart Circ Physiol. 2006;290(1):H146-53. doi: 10.1152/ajpheart.00583.2005.
33. Hatley ME, Srinivasan S, Reilly KB, Bolick DT, Hedrick CC. Increased production of 12/15 lipoxygenase eicosanoids accelerates monocyte/endothelial interactions in diabetic db/db mice. J Biol Chem. 2003;278(28):25369-75. doi: 10.1074/jbc.M301175200.
34. Ghosh S, An D, Pulinilkunnil T, Qi D, Lau HC, Abrahani A, et al. Role of dietary fatty acids and acute hyperglycemia in modulating cardiac cell death. Nutrition. 2004;20(10):916-23. doi: 10.1016/j.nut.2004.06.013.
35. Ghosh S, Qi D, An D, Pulinilkunnil T, Abrahani A, Kuo KH, et al. Brief episode of STZ-induced hyperglycemia produces cardiac abnormalities in rats fed a diet rich in n-6 PUFA. Am J Physiol Heart Circ Physiol. 2004;287(6):H2518-27. doi: 10.1152/ajpheart.00480.2004.
36. Farvid MS, Ding M, Pan A, Sun Q, Chiuve SE, Steffen LM, et al. Dietary linoleic acid and risk of coronary heart disease: a systematic review and meta-Analysis of prospective cohort studies. Circulation. 2014;130(18):1568-78. doi: 10.1161/CIRCULATIONAHA.114.010236.
37. DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-h diagnostic criteria. Arch Intern Med. 2001;161(3):397-405.
38. Zaruba MM, Theiss HD, Vallaster M, Mehl U, Brunner S, David R, et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell. 2009;4(4):313-23. doi: 10.1016/j.stem.2009.02.013.
39. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58(4):975-83. doi: 10.2337/db08-1193.
40. Hu X, Dai S, Wu WJ, Tan W, Zhu X, Mu J, et al. Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: role of the cardiac stromal cell derived factor-1 alpha CXCR4 axis. Circulation. 2007;116(6):654-63. doi: 10.1161/CIRCULATIONAHA.106.672451.
41. Perry RJ, Camporez JP, Kursawe R, Titchenell PM, Zhang D, Perry CJ, et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell. 2015;160(4):745-58. doi: 10.1016/j.cell.2015.01.012.
42. Mega C, Vala H, Rodrigues-Santos P, Oliveira J, Teixeira F, Fernandes R, et al. Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties. Diabetol Metab Syndr. 2014;6(1):42. doi: 10.1186/1758-5996-6-42.
43. Ferreira L, Teixeira-de-Lemos E, Pinto F, Parada B, Mega C, Vala H, et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediat Inflamm. 2010;2010:592760. doi: 10.1155/2010/592760.
44. Goncalves A, Leal E, Paiva A, Teixeira Lemos E, Teixeira F, Ribeiro CF, et al. Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model. Diab Obes Metab. 2012;14(5):454-63. doi: 10.1111/j.1463-1326.2011.01548.x.
45. Mega C, de Lemos ET, Vala H, Fernandes R, Oliveira J, Mascarenhas-Melo F, et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diab Res. 2011;2011:162092. doi: 10.1155/2011/162092.
46. Marques C, Mega C, Goncalves A, Rodrigues-Santos P, Teixeira-Lemos E, Teixeira F, et al. Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals. Mediat Inflamm. 2014;2014:538737. doi: 10.1155/2014/538737.
47. Finelli C, Sommella L, Gioia S, La Sala N, Tarantino G. Should visceral fat be reduced to increase longevity? Ageing Res Rev. 2013;12(4):996-1004. doi: 10.1016/j.arr.2013.05.007.
48. Ahren B. Are sulfonylureas less desirable than DPP-4 inhibitors as add-on to metformin in the treatment of type 2 diabetes? Curr Diab Rep. 2011;11(2):83-90. doi: 10.1007/s11892-011-0179-x.
49. Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-Analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2010;20(4):224-35. doi: 10.1016/j.numecd.2009.03.015.
50. Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging. 2010;3(2):195-201. doi: 10.1161/CIRCIMAGING.109.899377.
51. Theiss HD, Brenner C, Engelmann MG, Zaruba MM, Huber B, Henschel V, et al. Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from acute myocardial infarction (SITAGRAMI-Trial)-rationale, design and first interim analysis. Int J Cardiol. 2010;145(2):282-4. doi: 10.1016/j.ijcard.2009.09.555.